跳至主要内容
临床试验/NCT00252278
NCT00252278Unknown4 期

The Effect of a Once Daily Evening Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents

Rhode Island Hospital2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2005年11月最近更新:
适应症
相关药物

试验速览

阶段
4 期
入组人数
36
试验地点
2
主要终点
mean sleep onset latency

研究概览

简要总结

Children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) very commonly experience difficulty in initiating and maintaining sleep. Studies have shown that daytime sleepiness resulting from insufficient sleep can affect attention and learning. Therefore, treating insomnia in children with ADHD may not only improve sleep, but it could potentially improve ADHD symptoms as well.

The main purpose of this study is to examine the effects of atomoxetine on ADHD-related insomnia. Atomoxetine (Strattera®) is a non-stimulant drug used to treat ADHD symptoms in both children and adults, and there is evidence that it may also have a positive effect on sleep in children with ADHD. During the study, participants will receive either atomoxetine or placebo for a period of four weeks. We expect that the effects of atomoxetine on sleep will differ from those of placebo, with atomoxetine having a greater effect on improving sleep difficulties.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
6 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Boy or girl aged 6-17 years, inclusive, and English-speaking
  • Meet the DSM-IV criteria for Attention-Deficit/Hyperactivity Disorder
  • Have sleep initiation defined by:
  • difficulty initiating or maintaining sleep that is viewed as a problem by the child or caregiver
  • sleep onset delay that is not exclusively related to direct or rebound effects of psychostimulant treatment
  • Have a parent or legal guardian willing to participate in the study

排除标准

  • Have any other primary sleep disorder(s) (e.g. obstructive sleep apnea or periodic limb movement disorder)
  • Have a history of significant chronic medical (e.g. diabetes, severe asthma) or psychiatric (e.g. depression) illness
  • Have a history of chronic use of sedating (e.g. antihistamines) or alertness enhancing (e.g. caffeine) medications
  • Have a history of failure to respond to an adequate (defined as appropriate dose and adequate duration of therapy) previous trial with atomoxetine

结局指标

主要结局

mean sleep onset latency

parent and child-reported evening settling difficulties

次要结局

  • ADHD symptom improvement
  • night wakings, sleep duration, and sleep efficiency
  • daytime sleepiness
  • executive functions and functional outcomes/quality of life

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验